Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.44 |
| ▸ | F10 | P00742 | 3/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 2/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23201219 | 0.98 | F2 (0.49) | F2KDM4EALDH1A1MAPTAPEX1 | |
| SCHEMBL1232537 | 0.86 | HDAC6 (0.57) | F2KDM4EALDH1A1MAPTTPSAB1 | |
| SCHEMBL29941136 | 0.86 | HDAC6 (0.57) | F2KDM4EALDH1A1MAPTTPSAB1 | |
| Hydrochloric Acid SCHEMBL30387231 | 0.84 | KDM4E (0.56) | F2KDM4EALDH1A1MAPTTPSAB1 | |
| Hydrochloric Acid SCHEMBL23201220 | 0.84 | KDM4E (0.56) | F2KDM4EALDH1A1MAPTTPSAB1 | |
| Hydrochloric Acid SCHEMBL30882627 | 0.84 | KDM4E (0.56) | F2KDM4EALDH1A1MAPTTPSAB1 | |
| SCHEMBL6165236 | 0.83 | PLAU (0.40) | F2TPSAB1F10PRSS1PLG | |
| SCHEMBL476588 | 0.82 | AR (0.52) | KDM4EALDH1A1MAPTAPEX1RECQL | |
| SCHEMBL29858564 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1MAPTAPEX1RECQL | |
| SCHEMBL2396812 | 0.81 | HDAC6 (0.42) | KDM4EALDH1A1MAPTAPEX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007509176-A | — | — | 2007-04-12 | — | — | JP | claimed |
| EP-1682518-A1 | DICATIONIC TRIARYL ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005040132-A1 | DICATIONIC TRIARYL ANALOGS AS ANTI-PROTOZOAN AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-05-06 | — | — | WO | claimed |
| US-6867200-B1 | (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-15 | — | — | US | claimed |
| US-20030225036-A1 | Non-amidine containing protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | claimed |
| EP-1265897-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-18 | — | — | EP | claimed |
| WO-2001070743-A1 | NON-AMIDINE CONTAINING PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | claimed |
| EP-0960102-A1 | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN | Du Pont Pharmaceuticals Company (US) | 1999-12-01 | — | — | EP | claimed |
| WO-1999026941-A1 | SUBSTITUTED AMIDINOARYL DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1999026932-A1 | BY AMIDINO GROUP SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTICOAGULANTS | AXYS PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1998001428-A1 | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-01-15 | — | — | WO | claimed |
| US-4619942-A | Inhibition of Respiratory Syncytial virus-induced cell fusion by amidino compounds | UNIVERSITY OF NORTH CAROLINA (US) | 1986-10-28 | — | — | US | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-4397863-A | PROPHYLAXIS | RESEARCH TRIANGLE INSTITUTE (US) | 1983-08-09 | — | — | US | disclosed |
| US-4397863-A | PROPHYLAXIS | RESEARCH TRIANGLE INSTITUTE (US) | 1983-08-09 | — | — | US | disclosed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | disclosed |
| US-4324794-A | PREVENTION OF EPIDEMICS BY PROPHYLACTIC ADMINISTRATION | RESEARCH TRIANGLE INSTITUTE (US) | 1982-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225036-A1 | Non-amidine containing protease inhibitors | TFPI, SERPINE1, HABP2 | F2 5/4885KDM4E 2513/4885ALDH1A1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.